Fig. 6: Clinical evaluation of the erwinase-temsirolimus combination in PI3K-driven leukemia.
From: A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer
A Swimmer plots presenting the clinical history, treatment course, response, and outcome of the patients. B Bone marrow response, chest CT, and FDG-ET/CT evaluation of two patients presented a significant reduction in the tumor burden following treatment with the erwinase-temsirolimus association. Each dot represents a patient. C Oncoplot presenting the main oncogenetic characteristics of the treated patients.
